Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Despite widespread use of statins to reduce low-density lipoprotein cholesterol (LDL-C) and associated atherosclerotic cardiovascular risk, many patients do not achieve sufficient LDL-C lowering due to muscle-related side effects, indicating novel treatment strategies are required. Bempedoic acid (ETC-1002) is a small molecule intended to lower LDL-C in hypercholesterolemic patients, and has been previously shown to modulate both ATP-citrate lyase (ACL) and AMP-activated protein kinase (AMPK) activity in rodents. However, its mechanism for LDL-C lowering, efficacy in models of atherosclerosis and relevance in humans are unknown. Here we show that ETC-1002 is a prodrug that requires activation by very long-chain acyl-CoA synthetase-1 (ACSVL1) to modulate both targets, and that inhibition of ACL leads to LDL receptor upregulation, decreased LDL-C and attenuation of atherosclerosis, independently of AMPK. Furthermore, we demonstrate that the absence of ACSVL1 in skeletal muscle provides a mechanistic basis for ETC-1002 to potentially avoid the myotoxicity associated with statin therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 ETC-1002-CoA inhibits ACL and mediates β1-selective AMPK activation. Recombinant human ACL was incubated in the presence of the indicated concentrations of ETC-1002-CoA (a–c) or ETC-1002 (d), and (a) coenzyme A (CoA), (b) citrate or (c) ATP. Conversion of [14C]-citrate to [14C]-acetyl-CoA was measured in counts per minute (CPM). Recombinant human (e) AMPKα1β1γ1 and (f) AMPKα1β2γ1 complexes were incubated in the presence of the indicated concentrations of ETC-1002, ETC-1002-CoA, AMP or A-769622. (g) Structure of ETC-1002 and the biochemical reaction that generates ETC-1002-CoA acyl-CoA synthetase (ACS). ETC-1002-CoA/CoASH enzyme ACL kinetic analyses are single measures, and representative results from n=3 independent experiments shown; AMPK activity was determined by time-resolved fluorescence resonance energy transfer expressed as mean±s.e.m. of triplicate measures. (a) Ki calculated by Michaelis–Menten kinetic analysis.](https://figures.cochat.ai/paper-figures/02df10a0267b44eda297dc9dcee13726/liver-specific-atp-citrate-lyase-inhibition-by-bempedoic-acid-decreases-ldl-c-figure-1.jpg)
![Figure 2 Differentiation of ETC-1002 from the myotoxic effects of statins. [14C]-ETC-1002 (10 μM) conversion to [14C]-ETC-1002-CoA in human liver microsomes was determined in the presence of 30 μM unlabelled (a) monocarboxylic and (b) dicarboxylic saturated competitive fatty acid substrates. RH7777 cells were treated with negative control (Control) or Slc27a2 (ACSVL1) siRNA; n=6, for 48 h, and (c) ACSVL1 expression determined by western blot, and [14C]-ETC-1002-CoA synthesis determined; n=3. (d) Both control and Slc27a2 siRNA-treated RH7777 cells were treated with vehicle, ETC-1002 (30 μM) or atorvastatin (0.5 μM), and de novo cholesterol synthesis measured over 4 h; n=6 transfections. (e) Relative ACSVL1 expression in microsomes prepared from human liver, kidney and skeletal muscle (SkM). (f) ETC-1002-CoA synthetase activity in microsomes prepared from human liver and skeletal muscle; palmitate (10 μM) used as a positive control for skeletal muscle microsome viability. (g) ACSVL1 expression was measured in primary human hepatocytes and primary human skeletal muscle (SkM) cells by western blotting and expressed relative to β-actin. (h) Primary human myotubes were treated with vehicle (Veh.), simvastatin 10 μM (Simva), atorvastatin 10 μM (Atorva) or ETC-1002 100 μM in the presence of [14C]-glucose for 12 h, and incorporation into non-saponifiable lipids determined; or treated with 0.1–100 μM simvastatin, atorvastatin or ETC-1002 for 48 h and (i) cytotoxicity was measure by GF-AFC/bis-AAF-R110 cleavage, and (j) Caspase 3,7 activity (DEVD cleavage) determined. Data for myotube cytotoxicity assays are expressed as mean±s.e.m., n=2 performed in triplicate. Data for liver (n=50 donors pooled) and kidney (n=50 donors pooled) microsome preparations are representative of two independent experiments performed in duplicate, and expressed as mean±s.d. Data for human skeletal muscle microsomes (n=4 pooled donors) are the mean±s.e.m. of two independent experiments performed in triplicate. Multiple comparisons were made using an one-way ANOVA, Bonferroni's multiple comparisons test; *P<0.05.](https://figures.cochat.ai/paper-figures/aa53cfde988849fa938e4aa3379a9671/liver-specific-atp-citrate-lyase-inhibition-by-bempedoic-acid-decreases-ldl-c-figure-2.jpg)


![Figure 5 ACL suppression increases LDLR. (a) Primary human hepatocytes were treated with vehicle or ETC-1002 (100 μM) for 18 h in the presence of [3H]-H2O or pretreated with the indicated concentrations of ETC-1002 for 1 h, following a 3 h [14C]-acetate pulse. Counts incorporated into the non-saponifiable (sterols), and saponifiable (fatty acids) lipid fractions were determined and expressed as % vehicle. (b) Primary human hepatocytes were treated with vehicle, atorvastatin (0.5 μM) or ETC-1002 (100 μM) for 36 h and total intracellular cholesterol concentrations were determined in cell lysates. (c) Media was assayed for apoB by enzyme-linked immunosorbent assay. (d) PHHs were treated with ETC-1002 for the indicated time points and the apoB concentrations were measured in the media. (e) PHH were pre-labelled overnight with [14C]-oleate and the effects of ETC-1002 treatment on oleate-derived counts in the media determined at the indicated time points. PHH hepatocytes were treated with ETC-1002 and atorvastatin, and (f) mRNA levels for HMGR, SREBF2, PCSK9 and LDLR were determined by reverse transcription–quantitative PCR or (g) LDL receptor activity determined; A-769662 (10 μM). (h) RH7777 cells were treated with the indicated concentrations of ETC-1002 or atorvastatin (0.5 μM), and [14C]-lactate incorporation into cholesterol (Chol), cholesteryl esters (CE) and triglycerides determined. (i) LDLR-mediated DiI–LDL uptake in response to the indicated concentrations of ETC-1002±atorvastatin (0.5 μM). RH7777 cells were subjected to negative control (NC) or Acly siRNA-mediated gene silencing (n=3) and analysed for (j) ACL LDLR protein levels, or (k) LDLR-mediated DiI–LDL uptake. Data for PHH are expressed as mean±s.e.m. of n=2 donors performed in triplicate (a–c,f,g; except A-769662 treatment was 1 donor) or representative of two independent experiments showing similar results (d,e). (h) IC50 and (i) EC50 determinations were made using nonlinear curve fit model. Multiple comparisons were made using (a,j,k) unpaired Student's t-test or (b,c,f,g) an one-way ANOVA, Bonferroni's multiple comparisons test; *P<0.05.](https://figures.cochat.ai/paper-figures/bdd7bd8103b34bfd9b8c72b35fad6960/liver-specific-atp-citrate-lyase-inhibition-by-bempedoic-acid-decreases-ldl-c-figure-5.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bempedoic acid is a pro-drug that reduces cholesterol synthesis by inhibiting adenosine triphosphate (ATP) citrate lyase, with very limited musculoskeletal-related side effects.280”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [280]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081 · cited 1×
“Triacsin C is a potent inhibitor of ACSL1 and 4, and a weak inhibitor of ACSVL1 (refs 43–47).”
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Brown, M. S., & Goldstein, J. L. (1997) · Cell · doi:10.1016/s0092-8674(00)80213-5 · Cited by 3,834 · cited 1×
“Upregulation of the LDL receptor results in a new homeostatic state, where more cellular cholesterol is derived from blood LDL particles, thus reducing blood LDL-C 51–53 .”
The AMPK signalling pathway coordinates cell growth, autophagy and metabolism
Mihaylova, M. M., & Shaw, R. J. (2011) · Nature Cell Biology · doi:10.1038/ncb2329 · Cited by 2,923
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Cited by
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Targeting cancer metabolism in the era of precision oncology
Stine, Z. E., Schug, Z. T., Salvino, J. M., & Dang, C. V. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00339-6 · Cited by 1,189
New insights into activation and function of the AMPK
Steinberg, G. R., & Hardie, D. G. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00547-x · Cited by 1,006
Self-citationBempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
Nissen, S. E., Lincoff, A. M., Brennan, D., Ray, K. K., Mason, D., Kastelein, J. J. P., Thompson, P. D., Libby, P., Cho, L., Plutzky, J., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2215024 · Cited by 988
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1803917 · Cited by 807
Self-citationLipid metabolism in cancer: New perspectives and emerging mechanisms
Broadfield, L. A., Pane, A. A., Talebi, A., Swinnen, J. V., & Fendt, S.-M. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.04.013 · Cited by 758
AMP-activated protein kinase: the current landscape for drug development
Steinberg, G. R., & Carling, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0019-2 · Cited by 754
Self-citation2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
Mach, F., Koskinas, K. C., Roeters van Lennep, J. E., Tokgözoğlu, L., Badimon, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., De Backer, G. G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf190 · Cited by 688
Metabolic-associated fatty liver disease and lipoprotein metabolism
Heeren, J., & Scheja, L. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101238 · Cited by 646
“In hyperlipidemic mice on an atherogenic high fat diet, bempedoic acid suppressed hepatic DNL, corrected hyperlipidemia and reduced liver steatosis [119,126].”
BackgroundAMPK as a Therapeutic Target for Treating Metabolic Diseases
Day, E. A., Ford, R. J., & Steinberg, G. R. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.05.004 · Cited by 619
Self-citationDuan, Y., Gong, K., Xu, S., Zhang, F., Meng, X., & Han, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01125-5 · Cited by 538
“Therefore, inhibition of ACLY activity by bempedoic acid administration simply occurs to the liver, thereby avoiding the muscle-related side effects.(262) ACLY inhibition can also upregulate LDLR expression, which can make additional contributions to the reduction of plasma LDL-C levels.”
BackgroundGoldberg, A. C., Leiter, L. A., Stroes, E. S. G., Baum, S. J., Hanselman, J. C., Bloedon, L. T., Lalwani, N. D., Patel, P. M., Zhao, X., & Duell, P. B. (2019) · JAMA · doi:10.1001/jama.2019.16585 · Cited by 481
Self-citationEfficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance
Laufs, U., Banach, M., Mancini, G. B. J., Gaudet, D., Bloedon, L. T., Sterling, L. R., Kelly, S., & Stroes, E. S. G. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011662 · Cited by 432
“A key differentiator between statins and bempedoic acid is that bempedoic acid is a prodrug that requires activation by very-long-chain acyl-CoA synthetase-1, an enzyme that is absent in skeletal muscle.(13) The trial confirms the expectation that bempedoic acid does not induce muscle-related side effects.”
BackgroundInfluentialBallantyne, C. M., Banach, M., Mancini, G. B. J., Lepor, N. E., Hanselman, J. C., Zhao, X., & Leiter, L. A. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.002 · Cited by 422
Soppert, J., Lehrke, M., Marx, N., Jankowski, J., & Noels, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.019 · Cited by 407
Lipogenesis inhibitors: therapeutic opportunities and challenges
Batchuluun, B., Pinkosky, S. L., & Steinberg, G. R. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00367-2 · Cited by 399
Self-citationSpatiotemporal Control of Acetyl-CoA Metabolism in Chromatin Regulation
Sivanand, S., Viney, I., & Wellen, K. E. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2017.11.004 · Cited by 357
“From a therapeutic perspective, there is growing interest in targeting metabolic enzymes, including ACLY and ACSS2, in cancer and metabolic diseases [61,86].”
BackgroundMendelian Randomization Study of ACLY and Cardiovascular Disease
Ference, B. A., Ray, K. K., Catapano, A. L., Ference, T. B., Burgess, S., Neff, D. R., Oliver-Williams, C., Wood, A. M., Butterworth, A. S., Di Angelantonio, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1806747 · Cited by 342
Ballantyne, C. M., Laufs, U., Ray, K. K., Leiter, L. A., Bays, H. E., Goldberg, A. C., Stroes, E. S., MacDougall, D., Zhao, X., & Catapano, A. L. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319864671 · Cited by 358
Acetyl-CoA metabolism in cancer
Guertin, D. A., & Wellen, K. E. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00543-5 · Cited by 303
Lipid management in patients with chronic kidney disease
Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P., Heine, G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., Valdivielso, J. M., Malyszko, J., et al. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0072-9 · Cited by 273
Granchi, C. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.001 · Cited by 245
Physiological and pathological roles of lipogenesis
Jeon, Y. G., Kim, Y. Y., Lee, G., & Kim, J. B. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00786-y · Cited by 243
ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review
Feng, X., Zhang, L., Xu, S., & Shen, A.-Z. (2020) · Progress in Lipid Research · doi:10.1016/j.plipres.2019.101006 · Cited by 233
Targeting Foam Cell Formation in Atherosclerosis: Therapeutic Potential of Natural Products
Wang, D., Yang, Y., Lei, Y., Tzvetkov, N. T., Liu, X., Yeung, A. W. K., Xu, S., & Atanasov, A. G. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017178 · Cited by 226
“atherosclerosis in hypercholesterolemic ApoE mice (Pinkosky et al., 2016), LDLR mice (Samsoondar et al.”
BackgroundStructure of ATP citrate lyase and the origin of citrate synthase in the Krebs cycle
Verschueren, K. H. G., Blanchet, C., Felix, J., Dansercoer, A., De Vos, D., Bloch, Y., Van Beeumen, J., Svergun, D., Gutsche, I., Savvides, S. N., et al. (2019) · Nature · doi:10.1038/s41586-019-1095-5 · Cited by 198
Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia
Morrow, M. R., Batchuluun, B., Wu, J., Ahmadi, E., Leroux, J. M., Mohammadi-Shemirani, P., Desjardins, E. M., Wang, Z., Tsakiridis, E. E., Lavoie, D. C. T., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.05.004 · Cited by 199
Self-citationOptimizing cholesterol treatment in patients with muscle complaints
Rosenson, R. S., Baker, S., Banach, M., Borow, K. M., Braun, L. T., Bruckert, E., Brunham, L. R., Catapano, A. L., Elam, M. B., Mancini, G. B. J., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.752 · Cited by 193
The role of AMPK in macrophage metabolism, function and polarisation
Cui, Y., Chen, J., Zhang, Z., Shi, H., Sun, W., & Yi, Q. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04772-6 · Cited by 185
Banach, M., Duell, P. B., Gotto, A. M., Laufs, U., Leiter, L. A., Mancini, G. B. J., Ray, K. K., Flaim, J., Ye, Z., & Catapano, A. L. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.2314 · Cited by 187
The dawn of a new era of targeted lipid-lowering therapies
Tokgözoğlu, L., & Libby, P. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab841 · Cited by 171
“Sweet death”: Fructose as a metabolic toxin that targets the gut-liver axis
Febbraio, M. A., & Karin, M. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.09.004 · Cited by 173
“, 2017), whereas bempedoic acid (Nexletol), an ACLY inhibitor, is a clinically approved drug to treat hypercholesterolemia, as it lowers LDL cholesterol and attenuates atherosclerosis (Pinkosky et al., 2016).”
BackgroundStatin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy
Vinci, P., Panizon, E., Tosoni, L. M., Cerrato, C., Pellicori, F., Mearelli, F., Biasinutto, C., Fiotti, N., Di Girolamo, F. G., & Biolo, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111687 · Cited by 174
Lipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171
“the active metabolite bempedoic acid-CoA is generated by the activity of very-long-chain acyl CoA synthetase-1.(52) This”
Background2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
Mach, F., Koskinas, K. C., Roeters van Lennep, J. E., Tokgözoğlu, L., Badimon, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., De Backer, G. G., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120479 · Cited by 159
Role of Bempedoic Acid in Clinical Practice
Ballantyne, C. M., Bays, H. E., Catapano, A. L., Goldberg, A. C., Ray, K. K., & Saseen, J. J. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07147-5 · Cited by 167
“The lack of additional muscle symptoms with bempedoic acid when added to statins, even when bempedoic acid further lowered LDL-C, may be due to its distinct mechanism of action as compared with statins, and possibly because of a lack of exposure to the active bempedoyl-CoA metabolite in muscle tissue [17].”
BackgroundInfluentialEsquejo, R. M., Salatto, C. T., Delmore, J. E., Albuquerque, B., Reyes, A. R., Shi, Y., Moccia, R., Cokorinos, E., Peloquin, M., Monetti, M., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.04.009 · Cited by 158
“Primary hepatocytes were generated from ACC-DKI (Fullerton et al., 2013) and hepatocyte-specific AMPK knockout mice and fatty acid and sterol synthesis assessed, respectively, as previously described (Fullerton et al., 2013; Pinkosky et al., 2016).”
BackgroundMethodSelf-citationNicholls, S., Lincoff, A. M., Bays, H. E., Cho, L., Grobbee, D. E., Kastelein, J. J., Libby, P., Moriarty, P. M., Plutzky, J., Ray, K. K., et al. (2021) · American Heart Journal · doi:10.1016/j.ahj.2020.10.060 · Cited by 136
Macrophage ATP citrate lyase deficiency stabilizes atherosclerotic plaques
Baardman, J., Verberk, S. G. S., van der Velden, S., Gijbels, M. J., van Roomen, C. P. A. A., Sluimer, J. C., Broos, J. Y., Griffith, G. R., Prange, K. H. M., van Weeghel, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20141-z · Cited by 141
MASH: the nexus of metabolism, inflammation, and fibrosis
Steinberg, G. R., Carpentier, A. C., & Wang, D. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186420 · Cited by 150
“Acetyl-CoA is also used to generate cholesterol via the mevalonate pathway, and inhibition of ACLY by bempedoic acid leads to increases in the LDL receptor in the liver and reductions in LDL-cholesterol and atherosclerosis (102).”
Self-citationTargeting ATP-Citrate Lyase in Hyperlipidemia and Metabolic Disorders
Pinkosky, S. L., Groot, P. H. E., Lalwani, N. D., & Steinberg, G. R. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.09.001 · Cited by 126
Self-citationCicero, A. F. G., Fogacci, F., Hernández, A. V., & Banach, M. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003121 · Cited by 116
“Even though bempedoic acid acts on the same pathway as statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors), the lack of the activating enzyme in skeletal muscle may prevent the muscular adverse effects associated with statins [8].”
BackgroundNew and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B
Nurmohamed, N. S., Návar, A. M., & Kastelein, J. J. P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.079 · Cited by 125
Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials
Bays, H. E., Banach, M., Catapano, A. L., Duell, P. B., Gotto, A. M., Laufs, U., Leiter, L. A., Mancini, G. B. J., Ray, K. K., Bloedon, L. T., et al. (2020) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2020.08.009 · Cited by 103
Cui, D., Yu, X., Guan, Q., Shen, Y., Liao, J., Liu, Y., & Su, Z. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00321-3 · Cited by 140
“Upon activation, bempedoic acid is converted into bempedoic acid-CoA, which serves as a potent and selective inhibitor of ATP-citrate lyase (ACLY), the enzyme that catalyzes the committed step in cholesterol and fatty acid biosynthesis [230].”
AMPK and the Endocrine Control of Metabolism
Townsend, L. K., & Steinberg, G. R. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad012 · Cited by 119
Self-citationBempedoic Acid: First Approval
Markham, A. (2020) · Drugs · doi:10.1007/s40265-020-01308-w · Cited by 104
“The role of ACL in the LDL-C lowering effects of bempedoic acid was also evident in vitro studies in primary human hepatocytes [3].”
BackgroundInfluentialSamsoondar, J. P., Burke, A. C., Sutherland, B. G., Telford, D. E., Sawyez, C. G., Edwards, J. Y., Pinkosky, S. L., Newton, R. S., & Huff, M. W. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308963 · Cited by 98
Self-citationATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia
Burke, A. C., & Huff, M. W. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000390 · Cited by 91
Rubino, J., MacDougall, D. E., Sterling, L. R., Hanselman, J. C., & Nicholls, S. J. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.12.023 · Cited by 106
Bempedoic Acid: for Whom and When
Ruscica, M., Sirtori, C. R., Carugo, S., Banach, M., & Corsini, A. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01054-2 · Cited by 107
The vital role of ATP citrate lyase in chronic diseases
Khwairakpam, A. D., Banik, K., Girisa, S., Shabnam, B., Shakibaei, M., Fan, L., Arfuso, F., Monisha, J., Wang, H., Mao, X., et al. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-019-01863-0 · Cited by 94
Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
Martin, A., Lang, S., Goeser, T., Demir, M., Steffen, H., & Kasper, P. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01028-4 · Cited by 95
Penson, P. E., Bruckert, É., MARAIS, D. P., Reiner, Ž., Pirro, M., Sahebkar, A., Bajraktari, G., Mirrakhimov, E. M., Rizzo, M., Mikhailidis, D. P., et al. (2022) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12960 · Cited by 94
New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
Kim, K., Ginsberg, H. N., & Choi, S. H. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0198 · Cited by 98
“This property minimizes the exposure of the active drug to the non-hepatic tissue, such as the skeletal muscle [33].”
BackgroundYan, Y., Li, M., Lin, J., Ji, Y., Wang, K., Yan, D., Shen, Y., Wang, W., Huang, Z., Jiang, H., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.947387 · Cited by 87
Banach, M., Penson, P. E., Farnier, M., Fras, Z., Latkovskis, G., Laufs, U., Paneni, F., Parini, P., Pirro, M., Reiner, Ž., et al. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.03.001 · Cited by 84
Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome
Biolo, G., Vinci, P., Mangogna, A., Landolfo, M., Schincariol, P., Fiotti, N., Mearelli, F., & Girolamo, F. G. D. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1028355 · Cited by 85
Lipid Lowering Drugs: Present Status and Future Developments
Ruscica, M., Ferri, N., Santos, R. D., Sirtori, C. R., & Corsini, A. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00918-3 · Cited by 73
Patel, S. B., Wyne, K. L., Afreen, S., Belalcazar, L. M., Bird, M. D., Coles, S., Marrs, J. C., Peng, C. C., Pulipati, V. P., Sultan, S., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2024.09.016 · Cited by 85
Rubino, J., MacDougall, D. E., Sterling, L. R., Kelly, S. E., McKenney, J. M., & Lalwani, N. D. (2021) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2021.05.002 · Cited by 69
Self-citationMorrow, N. M., Burke, A. C., Samsoondar, J. P., Seigel, K. E., Wang, A., Telford, D. E., Sutherland, B. G., O’Dwyer, C., Steinberg, G. R., Fullerton, M. D., et al. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra119000542 · Cited by 71
“However, bempedoic acid lowered liver lipids, hepatocyte lipogenesis, LDL-C, and aortic cholesterol to the same extent in Apoe;Ampk1 double knockout mice as it did in Apoe mice (45).”
BackgroundResultSelf-citationAtherosclerotic dyslipidemia revealed by plasma lipidomics on ApoE −/− mice fed a high-fat diet
Chen, Y., Wen, S., Jiang, M., Zhu, Y., Ding, L., Shi, H., Dong, P., Yang, J., & Yang, Y. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.05.010 · Cited by 68
Parental metabolic syndrome epigenetically reprograms offspring hepatic lipid metabolism in mice
Jesus, D. F. D., Orime, K., Kamińska, D., Kimura, T., Basile, G., Wang, C., Haertle, L., Riemens, R. J. M., Brown, N. K., Hu, J., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci127502 · Cited by 68
“ATP-citrate lyase (ACLY) is a cytosolic enzyme responsible for the production of acetyl-CoA — a substrate for de novo cholesterol and fatty acid synthesis (32–35).”
Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
Bardolia, C., Amin, N. S., & Turgeon, J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.789931 · Cited by 73
“This may be due, in part, to the fact that very-long-chain acyl-CoA synthetase A, which is required for BDA activation, is not expressed in skeletal muscle (67).”
BackgroundLeiter, L. A., Banach, M., Catapano, A. L., Duell, P. B., Gotto, A. M., Laufs, U., Mancini, G. B. J., Ray, K. K., Hanselman, J. C., Ye, Z., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14645 · Cited by 73
“Bempedoic acid is a prodrug metabolized in the liver by very longchain acyl-CoA synthetase 1 (ACSVL1) to form the pharmacologically active bempedoic acid-CoA metabolite, which inhibits hepatic cholesterol synthesis and leads to upregulation of hepatic LDL receptors, increased uptake and clearance of LDL, and lowering…”
BackgroundBempedoic acid: effects on lipoprotein metabolism and atherosclerosis
Burke, A. C., Telford, D. E., & Huff, M. W. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000565 · Cited by 68
Mechanisms of Abnormal Lipid Metabolism in the Pathogenesis of Disease
Xu, L., Yang, Q., & Zhou, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158465 · Cited by 77
“In an animal model of As, Pinkosky that using In fact, ACLY uses distinct pathways to target macrophages and hepatocytes in order to achieve its dual regulatory actions [103,104]. benzoic acid to suppress ACLY expression in hepatocytes in lowering circulating LDL-C levels [105].”
BackgroundLipid Management in Patients Presenting With Acute Coronary Syndromes: A Review
Claessen, B. E. P. M., Guedeney, P., Gibson, C. M., Angiolillo, D. J., Cao, D., Lepor, N. E., & Mehran, R. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.018897 · Cited by 71
Lalwani, N. D., Hanselman, J. C., MacDougall, D. E., Sterling, L. R., & Cramer, C. T. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.05.003 · Cited by 72
Self-citationKumari, R., Deshmukh, R. S., & Das, S. (2019) · Nature Communications · doi:10.1038/s41467-019-12194-6 · Cited by 60
Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events
Raschi, E., Casula, M., Cicero, A. F. G., Corsini, A., Borghi, C., & Catapano, A. L. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108507 · Cited by 71
Molecular basis for acetyl-CoA production by ATP-citrate lyase
Wei, X., Schultz, K. C., Bazilevsky, G. A., Vogt, A. D., & Marmorstein, R. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0351-6 · Cited by 59
New Therapies for Primary Hyperlipidemia
Aguilar-Salinas, C. A., Gómez-Díaz, R. A., & Corral, P. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab876 · Cited by 67
AMP-activated protein kinase, fatty acid metabolism, and insulin sensitivity
Smith, B. K., & Steinberg, G. R. (2017) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000380 · Cited by 59
Self-citationACLY inhibition promotes tumour immunity and suppresses liver cancer
Gautam, J., Wu, J., Lally, J., McNicol, J. D., Fayyazi, R., Ahmadi, E., Oniciu, D. C., Heaton, S., Newton, R. S., Rehal, S., et al. (2025) · Nature · doi:10.1038/s41586-025-09297-0 · Cited by 69
“Cell-free assays revealed that, unlike bempedoic acid 30 , EVT0185-CoA inhibited rather than activated AMPKβ1-containing complexes (Extended Data Fig.”
Self-citationRuscica, M., Banach, M., Sahebkar, A., Corsini, A., & Sirtori, C. R. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1583209 · Cited by 62
“(2) ETC-1002 enhances the activity of AMP-activated protein kinase (AMPK) thus inhibiting the acetyl-CoA carboxylase (ACC) most likely by reduced production of malonyl-CoA, an inhibitor of carnitine palmitoyltransferase-1 (CPT-1).”
BackgroundInfluentialXiong, J., Zhou, P., Jiang, H., Huang, T., He, Y., Zhao, Z., Zang, Y., Choo, Y., Wang, X., Chittiboyina, A. G., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202109082 · Cited by 54
Future perspectives of the pharmacological management of diabetic dyslipidemia
Patti, A. M., Giglio, R. V., Παπάνας, Ν., Rizzo, M., & Rizvi, A. A. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1567328 · Cited by 58
“inactive form and can potentially avoid statin-associated myotoxicity [71].”
BackgroundEvaluating bempedoic acid for the treatment of hyperlipidaemia
Penson, P. E., McGowan, M. P., & Banach, M. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1280458 · Cited by 52
“The definitive mechanism of action of bempedoic acid has just been published [20].”
BackgroundSaeed, A., & Ballantyne, C. M. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.007 · Cited by 51
Current Options and Future Perspectives in the Treatment of Dyslipidemia
Muscoli, S., Ifrim, M., Russo, M., Candido, F., Sanseviero, A., Milite, M., Luozzo, M. D., Marchei, M., & Sangiorgi, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164716 · Cited by 56
“Furthermore, the skeletal muscle cannot activate prodrug due to the absence of the enzyme ACSVL1, resulting in the reduction of adverse muscle effects, which often complicate statin therapy [29,30].”
BackgroundInsulin Regulation of Hepatic Lipid Homeostasis
Uehara, K., Santoleri, D., Whitlock, A. E. G., & Titchenell, P. M. (2023) · Comprehensive Physiology · doi:10.1002/cphy.c220015 · Cited by 49
“Bempedoic acid directly inhibits ACLY to block fatty acid synthesis, ultimately leading to the upregulation of low-density lipoprotein (LDL) receptors, decreasing circulating LDL-cholesterol, and attenuating atherosclerosis (255, 256).”
Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis
Tummala, R., Gupta, M., Devanabanda, A. R., Bandyopadhyay, D., Aronow, W. S., Ray, K. K., Mamas, M. A., & Ghosh, R. K. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2059559 · Cited by 56
“acid ensures that it does not competitively interrupt the uptake of statins in the liver [17,18].”
BackgroundLiang, M., Wang, Q., Zhang, S., Lan, Q., Wang, R., Tan, E., Zhou, L., Wang, C., Wang, H., & Cheng, Y. (2024) · Advanced Materials · doi:10.1002/adma.202409015 · Cited by 52
Clinical Pharmacology of Statins: an Update
Ferri, N., & Corsini, A. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00844-w · Cited by 56
ATP-citrate lyase (ACLY) inhibitors as therapeutic agents: a patenting perspective
Granchi, C. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2067478 · Cited by 49
“ACLY inhibition by bempedoic-CoA conjugate decreased low-density lipoprotein-cholesterol (LDL-C) levels by reducing cholesterol biosynthesis and upregulating LDL receptor expression [60].”
BackgroundSun, Q., Niu, Q., Guo, Y., Zhuang, Y., Li, X., Liu, J., Li, N., Li, Z., Huang, F., & Qiu, Z. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c03105 · Cited by 46
Emerging roles of fatty acid metabolism in cancer and their targeted drug development
An, Q., Lin, R., Wang, D., & Wang, C. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114613 · Cited by 47
Burke, A. C., Telford, D. E., Sutherland, B. G., Edwards, J. Y., Sawyez, C. G., Barrett, P. H. R., Newton, R. S., Pickering, J. G., & Huff, M. W. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310676 · Cited by 46
“In Apoe mice, BemA reduced plasma cholesterol (−18%) and modestly attenuated aortic sinus lesions (−21%).(11) In Ldlr mice, BemA treatment attenuated diet-induced hypercholesterolemia (−41%), hypertriglyceridemia (−52%), hyperglycemia, hyperinsulinemia, hepatic steatosis, and adiposity.”
BackgroundMethodSelf-citationDevelopment of the novel ACLY inhibitor 326E as a promising treatment for hypercholesterolemia
Xie, Z., Zhang, M., Song, Q., Cheng, L., Zhang, X., Song, G., Sun, X., Gu, M., Zhou, C., Zhang, Y., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.06.011 · Cited by 46
Molusky, M. M., Hsieh, J., Lee, S. X., Ramakrishnan, R., Tascau, L., Haeusler, R. A., Accili, D., & Tall, A. R. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311212 · Cited by 45
Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?
Ruscica, M., Ferri, N., Macchi, C., Corsini, A., & Sirtori, C. R. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1498118 · Cited by 47
“The active derivative inhibits ACL in the liver, whereas no conversion occurs in skeletal muscle, lacking ACSVL 1 [177].”
BackgroundATP‐citrate lyase is an epigenetic regulator to promote obesity‐related kidney injury
Chen, Y., Deb, D. K., Fu, X., Yi, B., Liang, Y., Du, J., He, L., & Li, Y. C. (2019) · The FASEB Journal · doi:10.1096/fj.201900213r · Cited by 43
“In fact, targetingACL in the liveror tumorcells has generated beneficial therapeutic effects (19, 46).”
BackgroundGunta, S. P., O’Keefe, J. H., O’Keefe, E. L., & Lavie, C. J. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.02.007 · Cited by 45
Lazaropoulos, M. P., Gibb, A., Chapski, D. J., Nair, A. A., Reiter, A. N., Roy, R., Eaton, D., Bedi, K. C., Margulies, K. B., Wellen, K. E., et al. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00502-3 · Cited by 49
“For instance, bempedoic acid is a first-in-class ACLY inhibitor for dyslipidemia that is an alternative to statins because it avoids conversion to its active form in skeletal muscle 45 .”
Tian, M., Hao, F., Jin, X., Sun, X. J., Jiang, Y., Wang, Y., Li, D., Chang, T., Zou, Y., Peng, P., et al. (2021) · eLife · doi:10.7554/elife.62394 · Cited by 42
Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review
Ferri, N., Ruscica, M., Fazio, S., & Corsini, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13040943 · Cited by 51
“…from a prodrug (8-hydroxy-2,2,4,14-tetramethyl-pentadecanedioic acid) to an active metabolite catalyzed by enzyme “very long-chain acyl-CoA synthetase-1 (ACSVL1)” which occurs in hepatocytes and leads to the genesis of the powerful direct and competitive inhibitor, bempedoic acid-CoA [118].”
InfluentialBempedoic acid suppresses diet-induced hepatic steatosis independently of ATP-citrate lyase
Liu, J. Y., Kuna, R. S., Pinheiro, L. V., Nguyen, P. T., Welles, J. E., Drummond, J. M., Murali, N., Sharma, P. V., Supplee, J., Shiue, M., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.10.014 · Cited by 45
“On one hand, a reduction in steatosis was observed with shRNA-mediated silencing of ACLY in obese db/db mice, 20 as well as in a treatment paradigm on an MASH model, in which Acly deletion was induced in mice after several weeks of consuming a high-fat, high-fructose diet and being housed at thermoneutrality.”
BackgroundMethodInfluentialDai, L., Zuo, Y., You, Q., Zeng, H., & Cao, S. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320930585 · Cited by 44
Metadata
- Authors
- Pinkosky, S. L., Newton, R. S., Day, E. A., Ford, R. J., Lhotak, S., Austin, R. C., Birch, C. M., Smith, B. K., Filippov, S., Groot, P. H. E., Steinberg, G. R., & Lalwani, N. D.
- Affiliations
- Esperion Therapeutics (United States) (US)
- McMaster University (CA)
- St. Joseph’s Healthcare Hamilton (CA)
- Corresponding author
- Pinkosky, Stephen L.
- Steinberg, Gregory R.
- Venue
- Nature Communications
- Published
- 2016-11-28
- Volume
- 7
- Issue
- 1
- Pages
- 13457-13457
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5133702
- OpenAlex
- W2558991743
- Cited by
- 498
- References
- 73
- Citations by year
- 2026: 63 · 2025: 50 · 2024: 76 · 2023: 79 · 2022: 55 · 2021: 67 · 2020: 50 · 2019: 24 · 2018: 21 · 2017: 10 · 2016: 1
- FWCI
- 21.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Funders
- Amgen
- Heart and Stroke Foundation of Canada
- McMaster University
- Esperion Therapeutics
- Amgen Canada
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- bempedoic acid, ATP citrate lyase, LDL cholesterol lowering, atherosclerosis, prodrug activation, LDL receptor upregulation, AMPK, hypercholesterolemia, skeletal muscle
- MeSH terms
- Adenylate Kinase, Animals, ATP Citrate (pro-S)-Lyase, Dicarboxylic Acids, Enzyme Activation, Enzyme Inhibitors, Fatty Acids, Humans, Cholesterol, LDL, Liver, Mice, Inbred C57BL, Models, Biological, Organ Specificity, Receptors, LDL, Up-Regulation, Mice, Knockout, Disease Progression, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hepatocytes, Atherosclerosis, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.